Knight Therapeutics Inc. (TSE:GUD – Get Free Report) reached a new 52-week high on Friday. The company traded as high as C$12.19 and last traded at C$12.03, with a volume of 39,122 shares traded. The stock had previously closed at C$12.05.
Knight Therapeutics Price Performance
The company has a debt-to-equity ratio of 4.22, a current ratio of 2.40 and a quick ratio of 1.79. The stock has a 50 day simple moving average of C$10.79 and a two-hundred day simple moving average of C$8.79. The company has a market cap of C$1.18 billion, a price-to-earnings ratio of 75.12, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.51.
Knight Therapeutics (TSE:GUD – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported C($0.03) EPS for the quarter. Knight Therapeutics had a return on equity of 2.03% and a net margin of 2.84%. The company had revenue of C$136.74 million for the quarter. On average, equities research analysts predict that Knight Therapeutics Inc. will post 0.10 earnings per share for the current fiscal year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.
See Also
- Five stocks we like better than Knight Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
